Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 1Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 5Dermatologic 4Breast 4Thoracic 3Other hematologic neoplasm 3Lymphoid 3Sarcoma 2Head & Neck 2Plasma cell 1Other solid neoplasm 1Myeloid 1Endocrine 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Solitary Fibrous Tumor, Pleural 1Mesothelioma, Malignant 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 551Pemetrexed 404Cisplatin 401Paclitaxel 273Docetaxel 255Gemcitabine 218pembrolizumab 191Bevacizumab 190Erlotinib Hydrochloride 184Radiotherapy 181Etoposide 147durvalumab 140Nivolumab 134Drug Therapy 127osimertinib 107atezolizumab 92Gefitinib 74Radiosurgery 72anlotinib 69Vinorelbine 68tislelizumab 52Irinotecan 51Ipilimumab 50130-nm albumin-bound paclitaxel 50Taxes 48Surgical Procedures, Operative 46Cetuximab 46sintilimab 45Albumin-Bound Paclitaxel 45apatinib 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Pharmacogenomic Testing × Thoracic × Clear all
NCT02399371 2026-05-08

Pembrolizumab in Treating Patients With Malignant Mesothelioma

University of Chicago

Phase 2 Completed
65 enrolled 12 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT01557959 2018-06-29

Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Wake Forest University Health Sciences

Phase 2 Completed
45 enrolled 9 charts
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung

NCT00245063 2014-10-02

AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
25 enrolled 5 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡